May-2022 | Dorzagliatin add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled phase 3 trial | Yang, Wenying; Zhu, Dalong; Gan, Shenglian; Dong, Xiaolin; Su, Junping; Li, Wenhui; Jiang, Hongwei; Zhao, Wenjuan; Yao, Minxiu; Song, Weihong; Lu, Yibing; Zhang, Xiuzhen; Li, Huifang; Wang, Guixia; Qiu, Wei; Yuan, Guoyue; Ma, Jianhua; Li, Wei; Li, Ziling; Wang, Xiaoyue; Zeng, Jiao'e; Yang, Zhou; Liu, Jingdong; Liang, Yongqian; Lu, Song; Zhang, Huili; Liu, Hui; Liu, Ping; Fan, Kuanlu; Jiang, Xiaozhen; Li, Yufeng; Su, Qing; Ning, Tao; Tan, Huiwen; An, Zhenmei; Jiang, Zhaoshun; Liu, Lijun; Zhou, Zunhai; Zhang, Qiu; Li, Xuefeng; Shan, Zhongyan; Xue, Yaoming; Mao, Hong; Shi, Lixin; Ye, Shandong; Zhang, Xiaomei; Sun, Jiao; Li, Ping; Yang, Tao; Li, Feng; Lin, Jingna; Zhang, Zhinong; Zhao, Ying; Li, Ruonan; Guo, Xiaohui; Yao, Qi; Lu, Weiping; Qu, Shen; Li, Hongmei; Tan, Liling; Wang, Wenbo; Yao, Yongli; Chen, Daoxiong; Li, Yulan; Gao, Jialin; Hu, Wen; Fei, Xiaoqiang; Wu, Tianfeng; Dong, Song; Jin, Wenlong; Li, Chenzhong; Zhao, Dong; Feng, Bo; Zhao, Yu; Zhang, Yi; Li, Xiaoying; Chen, Li |